Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IITreatmentCompleted18 and overOther09-094

Trial Description


Researchers from Memorial Sloan-Kettering Cancer Center, in collaboration with The New York Presbyterian Hospital-Weill Medical College of Cornell University, are conducting a study of a medicinal mushroom extract called Maitake (pronounced my-tock-e).

Laboratory studies show that Maitake can reduce the growth of cancer in animals. The Maitake does not kill cancer cells directly. It is believed to work through the immune system (the body's defense system against infection). Our test tube, animal and human dose determining studies show that Maitake can enhance immune function. We are conducting this study to see whether Maitake improves the neutrophil count and function in patients with MDS. The neutrophils are white blood cells which help to fight infection.

Eligibility Criteria

Inclusion Criteria:

  • MSKCC patients age 18 or older able to sign informed consent
  • Absolute Neutrophil count >0.5 K/mcL
  • Diagnosis of MDS by bone marrow biopsy
  • Patient not a candidate for aggressive standard treatment

Exclusion Criteria:

  • IPSS (High risk)
  • History of AML
  • History of Stem Cell transplant
  • Known history of HIV+
  • Allergy to mushrooms
  • Bone Marrow blasts >10%


Inclusion Criteria

  • Age ≥55 years

Exclusion Criteria

  • Currently taking corticosteroids or other immunosuppressants
  • Known history of HIV+
  • Current or previous malignancy or hematology disorder except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for > 3 years

Trial Contact Information

Trial Lead Organizations/Sponsors

Memorial Sloan-Kettering Cancer Center

  • Yukiguni Maitake Corporation of America
  • New York Weill Cornell Cancer Center at Cornell University
Kathleen Wesa, MD, Principal Investigator

Link to the current record.
NLM Identifier NCT01099917 processed this data on April 09, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to